ARCHIVES

Phase III Trial of Imbruvica Halted, Following Increases in Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 1 | January 31, 2014

Download PDF Visit The Full Archive

Related Articles

NCI Launches $18M Program to Encourage Produce Consumption

July 17, 1992

Also R01 payline likely to fall below 20th percentile in FY04.

September 26, 2003

Pharmacia Corp. Forms $1 Million Fund To Support Anthracycline Research.

June 2, 2000

In Brief: BMS Oncology Names New VP, Marketing; Hortobagyi Wins Freyer Medal; Prerez Honored

October 24, 1997

NCI, FDA Are Feuding Again, This Time Overcharge That DCT Moved Too Slowly On Toxicity Notification

April 10, 1981

In Brief: Shingleton To Head AACI; Saunders To Get Two More Jobs At U. Texas Medical Branch

January 21, 1977